Last reviewed · How we verify
dalpiciclib + capecitabine + endocrine therapy
Dalpiciclib is a CDK4/6 inhibitor that blocks the cell cycle, while capecitabine is a chemotherapy medication that interferes with DNA synthesis, and endocrine therapy targets hormone receptors to slow cancer growth.
Dalpiciclib is a CDK4/6 inhibitor that blocks the cell cycle, while capecitabine is a chemotherapy medication that interferes with DNA synthesis, and endocrine therapy targets hormone receptors to slow cancer growth. Used for HR-positive, HER2-negative advanced or metastatic breast cancer.
At a glance
| Generic name | dalpiciclib + capecitabine + endocrine therapy |
|---|---|
| Sponsor | Fujian Cancer Hospital |
| Drug class | CDK4/6 inhibitor + chemotherapy + endocrine therapy |
| Target | CDK4/6, estrogen receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Dalpiciclib works by inhibiting the CDK4/6 enzymes, which are involved in cell cycle progression. Capecitabine is a prodrug that is converted into 5-fluorouracil, a chemotherapy agent that interferes with DNA synthesis. Endocrine therapy, in this case, likely involves targeting hormone receptors such as estrogen receptors to slow cancer growth.
Approved indications
- HR-positive, HER2-negative advanced or metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Vomiting
- Hand-foot syndrome
Key clinical trials
- Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment (PHASE3)
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer (PHASE3)
- Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial (PHASE2)
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: